Latest Conference Articles

Triplet therapy of ciforadenant, nivolumab, and ipilimumab shows safety but lacks efficacy in advanced clear cell kidney cancer.

A groundbreaking study reveals the effectiveness of dabrafenib and trametinib in treating advanced thyroid cancer, showcasing significant survival benefits.

Combination therapy of percutaneous hepatic perfusion with immune checkpoint inhibitors shows promising survival rates in metastatic uveal melanoma patients.

Recent studies reveal that triplet therapies significantly enhance progression-free survival in patients with endocrine-resistant breast cancer.

Camrelizumab and famitinib significantly enhance progression-free survival in recurrent cervical cancer compared to traditional chemotherapy, offering a promising new treatment option.

Bemarituzumab combined with mFOLFOX6 shows promising overall survival benefits in advanced FGFR2b-overexpressing gastric cancer, despite safety concerns.

New findings from the EMBARK trial reveal enzalutamide significantly reduces mortality risk in high-risk prostate cancer patients, enhancing treatment options.

Alectinib shows remarkable 4-year survival rates in early-stage ALK-positive lung cancer, outperforming chemotherapy in disease-free survival and CNS recurrence.

Atezolizumab significantly enhances survival in ctDNA-positive muscle-invasive bladder cancer patients, addressing critical treatment gaps post-surgery.

Pembrolizumab significantly improves survival rates in early-stage non-small cell lung cancer, establishing a new standard of care in perioperative therapy.

Atezolizumab significantly enhances disease-free and overall survival in ctDNA-positive muscle-invasive bladder cancer patients, reshaping treatment strategies.

Zanzalintinib combined with atezolizumab significantly improves overall survival in metastatic colorectal cancer compared to regorafenib, offering new hope for patients.

Telisotuzumab adizutecan shows promising antitumor activity in advanced pancreatic cancer, with manageable safety and significant clinical benefits in a phase 1 study.

Combination therapy with sacituzumab govitecan and pembrolizumab enhances quality of life and delays physical decline in metastatic triple-negative breast cancer patients.

Disitamab vedotin plus toripalimab significantly enhances survival rates in HER2-expressing advanced urothelial carcinoma, outperforming standard chemotherapy.

New findings reveal that perioperative enfortumab vedotin and pembrolizumab significantly enhance survival rates in muscle-invasive bladder cancer patients.

Combination therapy with datopotamab deruxtecan and rilvegostomig shows significant antitumor activity in advanced urothelial cancer patients.

A phase 2 study reveals lenvatinib and everolimus significantly improve progression-free survival in metastatic clear cell RCC compared to cabozantinib.

New triplet therapy combining belzutifan, pembrolizumab, and lenvatinib shows promising efficacy for advanced clear cell renal cell carcinoma, outperforming other regimens.

The OPTIC RCC trial reveals promising outcomes for patients with angiogenic tumors treated with cabozantinib and nivolumab, showcasing high response rates and tumor reduction.

New findings reveal significant PFS benefits of T-DXd plus pertuzumab over traditional therapies for HER2-positive advanced breast cancer patients.

Datopotamab deruxtecan significantly enhances survival rates in first-line treatment for metastatic triple-negative breast cancer, offering new hope for patients.

Sacituzumab tirumotecan significantly improves progression-free survival in EGFR-mutated non-small cell lung cancer compared to traditional chemotherapy.

Raludotatug deruxtecan (R-DXd) demonstrates significant antitumor activity and manageable safety in platinum-resistant ovarian cancer, paving the way for further studies.

Enfortumab vedotin and pembrolizumab show promising first-line efficacy in treating recurrent metastatic head and neck cancer, with significant response rates.

Iza-bren shows significant improvement in response rates for recurrent nasopharyngeal carcinoma compared to chemotherapy, offering new hope for patients.

Zipalertinib shows promising efficacy in treating non-small cell lung cancer with CNS metastases, highlighting its potential as a new therapeutic option.

Tislelizumab enhances treatment outcomes in esophageal squamous cell carcinoma, showing improved response rates and survival compared to standard chemoradiotherapy.

Trastuzumab rezetecan significantly improves progression-free survival in HER2-positive breast cancer, outperforming standard treatments in a pivotal trial.